# Evelo Biosciences, Inc. (EVLO)

> Source: Nexqual · https://nexqual.com/EVLO · data as of 2026-10-21 20:00 UTC · cite as "Nexqual, Evelo Biosciences, Inc. (EVLO), nexqual.com/EVLO" · informational, not investment advice.

**Price:** USD 0 (-50.00% on the day) · last close of Oct 21, 2026; US market pre market, not a live price. Prev close 0 · day 0–0 · 52w 0–0 · market cap $2K · PNK

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -80.0% vs S&P 500 +14.9%; 5Y -100.0% vs S&P 500 +80.3%.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -80.0% | -100.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -80.1% | -94.2% |
| Volatility (annualized) | 374.7% | 482.8% |
| Max drawdown | -80.0% (Oct 2025→Dec 2025) | -100.0% (Nov 2021→Jun 2024) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/EVLO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends 2024-03-31) | — | — | — | $0 | — |
| Current fiscal year (ends 2023-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |